Ajooni Biotech Q1FY27: Revenue Doubles but Profit Declines
Ajooni Biotech Ltd · Outcome · 14 Aug 2026, 10:52 pm
Ajooni Biotech Q1FY27: Revenue Doubles but Profit Declines Ajooni Biotech reported a mixed performance for Q1 ended 30-Jun'26. Revenue from operations doubled to ₹6,349.07 lakh, a 103.1% YoY increase from ₹3,126.77 lakh. However, Net Profit declined by 44.7% YoY to ₹43.18 lakh from ₹78.14 lakh in the prior year's quarter. Sequentially, revenue grew 4.7% while profit fell sharply by 54.4%. The profit decline was driven by significantly higher material costs, which rose 112.7% YoY, and a 469% YoY surge in finance costs, compressing margins despite the strong top-line growth.
Original exchange filing (PDF)
More announcements from Ajooni Biotech Ltd
- Ajooni Biotech Limited has submitted to the Exchange, the unaudited financial results for the period ended September 30, 2026. · 13 Nov 2026
- AJOONI BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- To consider and approve the unaudited financial results for the period ended September 30, 2026 · 13 Nov 2026
- Ajooni Biotech Limited has informed the Exchange regarding 'Undertaking of functional website'. · 19 Oct 2026
- Ajooni Biotech Limited has informed the Exchange regarding 'Confirmation Certificate as per Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the Quarter Ended on 30th June, 2026'. · 15 Oct 2026
- Ajooni Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. · 14 Aug 2026
- Ajooni Biotech Limited has informed the Exchange regarding allotment of 9000000 securities pursuant to Preferential Issue at its meeting held on August 12, 2026 · 12 Aug 2026
- AJOONI BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 14-Aug-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2026 . · 14 Aug 2026
